AIO-Studien-gGmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB
Phase 2
Terminated
- Conditions
- Activating EGFR MutationNon-squamous Non-small Cell Lung Cancer Stage IIIANon-squamous Non-small Cell Lung Cancer Stage IIIBNSCLCNon-squamous Non-small Cell Lung Cancer Stage II
- Interventions
- First Posted Date
- 2014-12-29
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 1
- Registration Number
- NCT02326285
- Locations
- 🇩🇪
Pius-Hospital, Oldenburg, Germany
A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
Phase 2
Terminated
- Conditions
- Lung CancerProgressive Brain MetastasesBreast CancerRecurrent Brain Metastases
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 8
- Registration Number
- NCT02166658
- Locations
- 🇩🇪
Kliniken Nordoberpfalz, AG Klinikum Weiden, Medizinische Kliniken I, Weiden, Bayern, Germany
Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
Phase 2
Completed
- Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal JunctionEsophageal AdenocarcinomaGastric NeoplasmGastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaEsophageal Neoplasms
- Interventions
- Drug: Chemotherapy by Investigator's choice
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 242
- Registration Number
- NCT02128243
- Locations
- 🇩🇪
NCT-Med. Onkologie, Heidelberg, Baden-Württemberg, Germany
Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
Phase 2
Completed
- Conditions
- Ductal Adenocarcinoma of the Pancreas
- Interventions
- Drug: Gem/nab-PacDrug: FOLFIFINOX
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 168
- Registration Number
- NCT02125136
- Locations
- 🇩🇪
Universitätsklinikum Würzburg/Comprehensive Cancer Center Mainfranken, Würzburg, Bayern, Germany
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Phase 2
Completed
- Conditions
- Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3Neuroendocrine Carcinoma, Grade 3
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 40
- Registration Number
- NCT02113800
- Locations
- 🇩🇪
Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Campus Virchow-Klinikum, Berlin, Germany
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
Phase 2
Completed
- Conditions
- Ductal Adenocarcinoma of the PancreasResectable Pancreatic Cancer
- Interventions
- Drug: adjuvant nab-paclitaxel/gemcitabineDrug: perioperative nab-paclitaxel/gemcitabine
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 127
- Registration Number
- NCT02047513
- Locations
- 🇩🇪
University of Ulm, Dept. of Internal Medicine I, Ulm, Germany
Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: Maintenance ChemotherapyDrug: mFOLFOX6 (Within re-induction phase)
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 387
- Registration Number
- NCT01991873
- Locations
- 🇩🇪
St.-Antonius-Hospital Eschweiler, Eschweiler, Germany
🇩🇪Zentrum für Tumorbiologie und Integrative Medizin, Klinikum Wilhelmshaven, Wilhelmshaven, Germany
Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
Phase 2
Completed
- Conditions
- Ras-wildtype Colorectal Cancer
- Interventions
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 88
- Registration Number
- NCT01668498
- Locations
- 🇩🇪
Universitätsklinikum Mannheim, III. Medizinische Klinik, Mannheim, Germany
Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer
Phase 3
Terminated
- Conditions
- Esophageal Squamous Cell Cancer
- Interventions
- Drug: Cisplatin, 5-FU
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 300
- Registration Number
- NCT01627379
- Locations
- 🇩🇪
Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Rheinland-Pfalz, Germany
A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer
- Conditions
- the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- AIO-Studien-gGmbH
- Registration Number
- NCT01626781
- Locations
- 🇩🇪
Universitätsmedizin Mannheim, III. Medizinische Klinik, Mannheim, Germany